Oxford University Innovations Ltd. has synthesized hypoxia-activated proteolysis targeting chimeras (hypoxia-activated PROTACs; HAP-TAC) comprising a hypoxia-activated moiety modified E3 ubiquitin ligase-binding moiety coupled to a protein targeting moiety through a linker reported to be useful for the treatment of cancer.
Shanghai Yidi Biotechnology Co. Ltd. has disclosed neutrophil elastase (ELANE; leukocyte elastase) inhibitors reported to be useful for the treatment of pain and respiratory tract inflammation.
Researchers from Lund University and collaborators have investigated the potential of selectively targeting TUBG1 as a therapeutic strategy in cancer treatment.
In a newly published study, researchers from the CSIR Institute of Genomics and Integrative Biology and collaborators further explored the potential of Cdk5 targeting as a therapeutic approach for type 2 diabetes and cognitive deterioration.
FK506-binding protein-like (FKBPL) is an immunophilin protein family member with critical functions in physiological and pathological angiogenesis. Its therapeutic peptide derivative AD-01, currently a preclinical peptide candidate, targets angiogenesis via CD44. AD-01 acts both as a vascular stabilizer and an anti-inflammatory agent under pro-inflammatory conditions.
Northstrive Biosciences Inc., a subsidiary of PMGC Holdings Inc., has entered into a development and license agreement with Yuva Biosciences Inc. to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions using Yuva’s mitochondrial science-focused platform Mitonova, powered by AI.
Mutations in the oncogene KRAS are widespread in several human cancers, including pancreatic ductal adenocarcinomas (92%), colorectal carcinomas (49%) and lung adenocarcinomas (35%). These mutations hyperactivate various downstream signaling pathways, including the MAPK and PI3K/ AKT pathways. In KRAS-mutant tumors, both primary and acquired resistances are common.
Briacell Therapeutics Corp.’s subsidiary, Briapro Therapeutics Corp., is developing novel, high affinity antibodies to B7-H3 using molecular modeling techniques. As both an immune checkpoint molecule that regulates T-cell activity and a cell surface molecule expressed on many types of cancer cells, B7-H3 is a promising drug target.
Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These relapses are driven by insufficient persistence of CAR T cells, allowing for antigen-positive B-ALL re-emergence and loss of the targeted epitope either in isolation or as part of lineage-switching.
RSS
